HSV thymidine kinase gene therapy
Alternative Names: Retrovector™Latest Information Update: 22 Jul 2010
Price :
$50 *
At a glance
- Originator AVAX Technologies; Edison Biotechnology Institute; Novartis; Scientific Institute San Raffaele; Universite Pierre et Marie Curie
- Developer AVAX Technologies; Aventis Gencell; Edison Biotechnology Institute; Human Gene Therapy Research Institute (Des Moines); Novartis; Scientific Institute San Raffaele
- Class Gene therapies
- Mechanism of Action Thymidine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain cancer; Glioma; Graft-versus-host disease; Leukaemia; Liver cancer; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Ovarian cancer; Renal cancer
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 20 May 2002 Interneuron Pharmaceuticals is now called Indevus Pharmaceuticals